Page last updated: 2024-12-10
l803087
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
L803087: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
L-803087 : A fluoroindole that is 1H-indole substituted by phenyl, 4-{[(2S)-5-carbamimidamido-1-methoxy-1-oxopentan-2-yl]amino}-4-oxobutyl, fluoro and fluoro groups at positions 2, 3, 5 and 7, respectively. It is a selective nonpeptidic agonist of the somatostatin subtype-4 (SST4) receptor with Ki of 0.7 nM. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5311374 |
| CHEMBL ID | 1450103 |
| MeSH ID | M0392010 |
Synonyms (15)
| Synonym |
|---|
| gtpl2082 |
| l803087 |
| l-803,087 |
| NCGC00161823-01 , |
| methyl (2s)-5-(diaminomethylideneamino)-2-[4-(5,7-difluoro-2-phenyl-1h-indol-3-yl)butanoylamino]pentanoate |
| l-803087 |
| 217480-26-7 |
| CHEMBL1450103 |
| n2-(4-(5,7-difluoro-2-phenyl-1h-indol-3-yl)-1-oxobutyl)-l-arginine methyl ester |
| CS-0028987 |
| HY-108497 |
| Q27078440 |
| AT23608 |
| MS-29022 |
| AKOS040733566 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| somatostatin receptor agonist | An agonist that binds to and activates somatostatin receptors. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (7)
| Class | Description |
|---|---|
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| secondary carboxamide | A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). |
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| fluoroindole | An organofluorine compound that is a compound based on an indole skeleton, containing one or more fluorine atoms. |
| guanidines | Any organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas. |
| L-arginine derivative | A proteinogenic amino acid derivative resulting from reaction of L-arginine at the amino group, the carboxy group, or the guanidyl group, or from the replacement of any hydrogen of L-arginine by a heteroatom. |
| phenylindole | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Protein Targets (11)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 19.9526 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 56.2341 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 15.8489 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 7.9433 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 22.3872 | 0.3162 | 12.7657 | 31.6228 | AID881 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 22.3872 | 0.0063 | 8.2350 | 39.8107 | AID881 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Somatostatin receptor type 1 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0001 | 0.0013 | 0.0022 | AID203255; AID203256; AID203257 |
| Somatostatin receptor type 2 | Homo sapiens (human) | IC50 (µMol) | 7.0000 | 0.0004 | 0.0024 | 0.0140 | AID203392; AID203393; AID203394 |
| Somatostatin receptor type 2 | Homo sapiens (human) | Ki | 4.7200 | 0.0000 | 0.4091 | 4.7200 | AID1571206 |
| Somatostatin receptor type 4 | Homo sapiens (human) | IC50 (µMol) | 0.0042 | 0.0001 | 0.0021 | 0.0042 | AID203554; AID203555; AID203556 |
| Somatostatin receptor type 4 | Homo sapiens (human) | Ki | 0.0007 | 0.0006 | 0.2733 | 3.2000 | AID1571205 |
| Somatostatin receptor type 3 | Homo sapiens (human) | IC50 (µMol) | 7.0000 | 0.0004 | 0.1110 | 0.8800 | AID203412; AID203413; AID203414 |
| Somatostatin receptor type 5 | Homo sapiens (human) | IC50 (µMol) | 10.0000 | 0.0002 | 0.0472 | 0.3930 | AID203573; AID203574; AID203575 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (43)
Molecular Functions (13)
Ceullar Components (12)
Bioassays (20)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID203412 | Binding affinity towards human Somatostatin receptor type 3 using 125I-[Leu,DTrp,Tyr]SRIF-28 as radioligand | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. |
| AID203394 | Binding affinity towards human somatostatin receptor type 2 using [125I][Leu8,D-Trp22,Tyr25]SRIF-28 as radioligand. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. |
| AID1571206 | Displacement of 3-[125I]iodotyrosyl25-somatostatin-28 from recombinant human SST2 receptor expressed in CHOK1 cell membranes after 45 mins by scintillation counting method | |||
| AID203574 | Binding affinity at human Somatostatin receptor type 5 by [125I][Leu8,D-Trp22,Tyr25]SRIF-28 displacement. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. |
| AID203414 | Binding affinity towards human somatostatin receptor type 3 using [125I][Leu8,D-Trp22,Tyr25]SRIF-28 as radioligand. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. |
| AID203555 | Binding affinity at human Somatostatin receptor type 4 by [125I][Leu8,D-Trp22,Tyr25]SRIF-28 displacement. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. |
| AID203257 | Binding affinity towards human somatostatin receptor type 1 using [125I][Leu8,D-Trp22,Tyr25]SRIF-28 as radioligand. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. |
| AID203256 | Binding affinity at human Somatostatin receptor type 1 by [125I][Leu8,D-Trp22,Tyr25]SRIF-28 displacement. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. |
| AID203413 | Binding affinity at human Somatostatin receptor type 3 by [125I][Leu8,D-Trp22,Tyr25]SRIF-28 displacement. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. |
| AID1571205 | Displacement of 3-[125I]iodotyrosyl25-somatostatin-28 from recombinant human SST4 receptor expressed in CHOK1 cell membranes after 45 mins by scintillation counting method | |||
| AID203573 | Binding affinity towards human Somatostatin receptor type 5 using 125I-[Leu,DTrp,Tyr]SRIF-28 as radioligand | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. |
| AID203255 | Binding affinity towards human Somatostatin receptor type 1 using 125I-[Leu,DTrp,Tyr]SRIF-28 as radioligand | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. |
| AID203575 | Binding affinity towards human somatostatin receptor type 5 using [125I][Leu8,D-Trp22,Tyr25]SRIF-28 as radioligand. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. |
| AID203554 | Binding affinity towards human Somatostatin receptor type 4 using 125I-[Leu,DTrp,Tyr]SRIF-28 as radioligand | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. |
| AID203392 | Binding affinity towards human Somatostatin receptor type 2 using 125I-[Leu,DTrp,Tyr]SRIF-28 as radioligand | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 1. Lead identification using a betide scan. |
| AID203556 | Binding affinity towards human somatostatin receptor type 4 using [125I][Leu8,D-Trp22,Tyr25]SRIF-28 as radioligand. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling. |
| AID203393 | Binding affinity at human Somatostatin receptor type 2 by [125I][Leu8,D-Trp22,Tyr25]SRIF-28 displacement. | 2003 | Journal of medicinal chemistry, Dec-18, Volume: 46, Issue:26 | Novel sst(4)-selective somatostatin (SRIF) agonists. 2. Analogues with beta-methyl-3-(2-naphthyl)alanine substitutions at position 8. |
| AID1346359 | Human SST4 receptor (Somatostatin receptors) | 1998 | Science (New York, N.Y.), Oct-23, Volume: 282, Issue:5389 | Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 9 (52.94) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.46
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.46) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||